ALK and neoplasm: Recently larotrectinib, a pan-TRK inhibitor, and entrectinib, a pan-TRK, ALK, and ROS1 tyrosine kinase inhibitor, were the first tumor-agnostic-targeted therapies developed and approved in oncology for the treatment of pediatric and adult tumors that have an NTRK gene fusion [52].